New York, NY (Press Release) – Phosplatin Thera­peutics LLC, a clin­i­cal stage pharma­ceu­tical com­pany focused on on­col­ogy thera­peutics, to­day an­nounced that the United States Patent and Trade­mark Office (USPTO) has issued US Patent No. 10,668,080, entitled: "Phosphaplatin Compounds as Thera­peutics Agents for Treatment of Bone or Blood Cancers." The granted claims are directed to the use of (pyrophosphato)platinum(II) or (pyrophosphato)platinum(IV) complexes, in­clu­sive of the Com­pany's lead com­pound, PT-112, as thera­peutic agents for the treat­ment of bone and blood can­cers, such as mul­ti­ple myeloma, or solid tumor can­cers that metastasize to bone, such as metastatic castration re­sis­tant prostate can­cer (mCRPC).

"This issuance marks an im­por­tant addi­tional step in strengthening the pro­tec­tion of our in­tel­lec­tual prop­er­ty for PT-112, as we con­tinue to study it as both a mono­therapy and in com­bi­na­tion across a range of can­cers, in­clud­ing mCRPC and mul­ti­ple myeloma," said Robert Fallon, Pres­i­dent and Chief Exec­u­tive Of­fi­cer of Phosplatin Thera­peutics.

PT-112's pleiotropic mode of action avoids the drug re­sis­tance mech­a­nisms common to con­ven­tional anti-cancer ther­apy. Fur­ther, it leads to immunogenic cell death (ICD), a rare form of anti-cancer action that promotes an adaptive im­mune re­sponse to the tumor. PT-112 has been val­i­dated as an ICD-inducing agent, and also re­ported to induce durable re­sponses in Phase I patients at soft tissue sites of dis­ease, char­ac­ter­istic of im­mune in­volvement. The drug's pyrophosphate moiety, addi­tionally, is be­lieved to be responsible for directing it at highest con­cen­tra­tions to the mineralized bone (osteo­tropism).

"Beyond its other features, PT-112's osteo­tropism leads us to posit that it has attractive de­vel­op­ment oppor­tu­ni­ties re­lated to bone site of dis­ease," said Mr. Fallon. "This pat­ent issuance allows us to pur­sue such de­vel­op­ment with added con­fi­dence."

About PT-112

PT-112 is the first small mol­e­cule con­ju­gate of pyrophosphate devel­oped in on­col­ogy thera­peutics. PT-112 promotes immunogenic cell death (ICD), or the re­lease of damage asso­ci­ated molecular pat­terns (DAMPs) that lead to downstream im­mune effector cell recruitment in the tumor micro­en­vi­ron­ment. PT-112 rep­re­sents a po­ten­tial best-in-class small mol­e­cule inducer of this immun­o­log­i­cal form of can­cer cell death, and is under Phase II de­vel­op­ment. The first-in-human study of PT-112 dem­onstrated an attractive safety profile and evi­dence of long-lasting re­sponses among heavily pre-treated patients, and won "Best Poster" at the ESMO 2018 Annual Congress within the De­vel­op­mental Thera­peutics category. The novelty of its pyrophosphate moiety also re­­sults in osteo­tropism, or the propensity of the drug to reach the mineralized bone. This prop­er­ty is of interest in can­cer types that originate in bone, or fre­quently lead to metastatic bone in­volvement, such as metastatic castrate-resistant prostate can­cer (mCRPC). The first human clin­i­cal re­­sults in mCRPC were pre­sented at the 2020 Genitourinary Cancers Symposium on Feb­ru­ary 13, 2020.

About Phosplatin Thera­peutics

Phosplatin Thera­peutics is a privately held, clin­i­cal stage pharma­ceu­tical com­pany that holds ex­clu­sive global li­cense to phosphaplatins, a family of small mol­e­cules rationally de­signed to circumvent the mech­a­nisms of drug re­sis­tance and toxicity commonly asso­ci­ated with chemo­ther­a­peu­tic regi­mens. The com­pany's lead can­di­date, PT-112, is a novel chemical entity under clin­i­cal de­vel­op­ment that exhibits a unique com­bi­na­tion of properties, in­clud­ing immunogenic cell death and osteo­tropism. Clinical data gen­er­ated to date across three Phase I stud­ies have dem­onstrated single agent anti-cancer ac­­tiv­ity and an attractive tol­er­a­bil­ity profile. The com­pany's re­search and de­vel­op­ment work to date has spanned fifteen countries and been funded by private in­vestors and family investment offices in the United States, Europe and Asia, along with a sub-license agree­ment for the de­vel­op­ment, com­mer­cial­i­za­tion and use of PT-112 in Greater China. The com­pany also is sponsoring an on­go­ing clin­i­cal study of PT-112 in com­bi­na­tion with the PD-L1 in­hib­i­tor avelumab under a col­lab­o­ration agree­ment with Pfizer and Merck KGaA, Darmstadt, Germany (operating as EMD Serono in the US and Canada).

Source: Phosplatin Thera­peutics.